



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 51/12, 51/06	A1	(11) International Publication Number:	WO 97/33628
(43) International Publication Date: 18 September 1997 (18.09.97)		(21) International Application Number: PCT/US97/02075	
(22) International Filing Date: 13 February 1997 (13.02.97)		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LT, LV, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 613,904 11 March 1996 (11.03.96) US		Published With international search report.	
(71) Applicant: FOCAL, INC. [US/US]; 4 Maguire Road, Lexington, MA 02173 (US).		(74) Inventors: LEAVITT, Richard, D.; 406 Union Wharf, Boston, MA 02109 (US), AVILA, Luis, Z.; 23 Rockaway Lane, Arlington, MA 02174 (US).	
(74) Agent: PABST, Patra, L.; Amall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(43) Title: POLYMERIC DELIVERY OF RADIONUCLIDES AND RADIOPHARMACEUTICALS	
(57) Abstract			
Locally deposited polymer depots are used as a vehicle for the immobilization and local delivery of a radionuclide or radiopharmaceutical. Radionuclides are incorporated in their elemental forms, as inorganic compounds, or are attached to a larger molecule or incorporated into the polymer, by physical or chemical methods. Ancillary structure may be employed to control the rate of release. Standard radionuclides which have been used for local radiotherapy may be used, such as radionuclides of iodine, iridium, radium, cesium, yttrium or other elements.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CJ	Cote d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

POLYMERIC DELIVERY OF RADIONUCLIDES AND RADIOPHARMACEUTICALS

Background of the Invention

5 This relates to an improved method of local radiotherapy, and devices and compositions for accomplishing local radiotherapy.

Radiation has been used for cancer therapy and to control local healing in areas as diverse as preventing excessive scar formation or reducing lymphoid infiltration and proliferation. More recently, radiation has been used to inhibit restenosis following coronary artery or peripheral
10 artery angioplasty. Interstitial radiation by use of radioactivity incorporated into intravascular stents, delivery of radiation dose by use of catheters containing radioactive sources, and external beam radiotherapy have been used.

There are disadvantages to each of these approaches. When
15 radiation is delivered by an extracorporeal beam, the usual problems of limiting the exposure only to those tissues intended to be affected are encountered. Moreover, doses must often be subdivided, requiring more than one visit to the hospital by the patient. If radiation is to be delivered by a catheter or other temporarily-installed medical device, then the rate
20 of delivery of radiation from the device must be high. The active source will normally require careful shielding, even if relatively "soft" radiation, such as beta rays, is used. If administered in the same operation as balloon angioplasty or cardiac bypass, extra complications of an already complex and risky procedure are magnified. Delivery of radiation on a
25 permanently implanted device, or a biodegradable device that necessarily is eroded over a long period of time because it also provides structural support, severely limits the choice of radioisotope because of the need to limit the total delivered dose to the tissue, while simultaneously providing sufficient initial dose to achieve the required effect. Moreover, repetition
30 of the administration, if required, is not readily achieved.

-2-

The object of this invention is to provide an improved method for localized radiotherapy for the cure or alleviation of medical conditions.

Summary of the Invention

Locally deposited biodegradable polymer depots are used as a vehicle for the immobilization and local delivery of a radionuclide or radiopharmaceutical. Radionuclides are incorporated in their elemental forms, as inorganic compounds, or are attached to a larger molecule or incorporated into the polymer, by physical or chemical methods. Ancillary structures may be employed to control the rate of release. The depot is preferably made of a biodegradable material which is selected to degrade at a known rate under conditions encountered at the site of application. The depot is preferably fluent, or capable of being made fluent, so that it may be deposited at a site in a conforming manner by minimally invasive means. Examples of such materials are melted polymers which re-solidify at body temperature, and polymerizable materials which are polymerized at the site of deposition. The depot optionally is provided with means for controlling the rate of release of the radioactive compound. These means may include microparticles in which the radioactive compound is incorporated.

The use of the polymeric depots provides a way of immobilizing the source of energy from a radioactive source at a remote site within the body, which can be accessible by a less invasive surgical procedure, such as by catheter or laparoscopy. The duration and total dose of radiation can be controlled by a combination of choice of the radionuclide, control of the rate of degradation of the polymer, and control of the rate of release of the radionuclide from the depot. Following polymer degradation and/or release of the radionuclide, excretion from the body in urine and stool can be favored by administering pharmaceutical agents which favor excretion. For example, in the case of iodine radionuclides, excretion can be favored by blocking thyroid uptake of radioactive iodine

or iodinated compounds by systemic administration of non-radioactive iodine compounds, such as sodium iodide or Lugol's solution.

Detailed Description of the Invention

The polymeric depots provide a method of delivery of a radioactive agent to a local site of disease for treatment, such as for prevention of restenosis following angioplasty. The method has advantages over other methods of local radiation delivery in all applications, because the duration and intensity of the exposure can be altered by choosing radionuclides of differing physical half-life, and the biological half-life can be controlled by accelerating or retarding the rate of release of the radionuclide from the polymeric matrix. This provides a way to control local dosage of radiation without the need for physical removal of the implanted radionuclide. Radioactivity can thus be applied at any site in the body that is accessible by a less invasive procedure or catheter, for example, to a coronary artery or a tumor arterial supply. This also allows the application of interstitial, implanted radiotherapy while minimizing the exposure of the operator to radiation that is sometimes necessary when using other currently available methods of providing local radiotherapy.

Polymers

Polymers for forming the depot must be biodegradable, i.e., must dissolve into small molecules which can be removed by normal metabolic functions and/or excretion, under the conditions found at the site of application of the depot. In one aspect, the polymers may be slowly soluble under body conditions, for example, certain poloxamers, such as Pluronic™ F-68 (a polyethylene glycol-polyethylene oxide block copolymer marketed by BASF), which gel at body temperature and slowly dissolve over several days. In another aspect, the fluidity of the polymers is altered using temperature. For example, polymers can be melted by heating or by cooling (e.g., with Plurionics™), and applied to the site, where the polymer will re-solidify. Depot formation can also be

caused by other known means of coacervation, such as complexation of polymers with ions (e.g., alginate with calcium), direct coacervation of polymers (e.g., polyglutamic acid with polylysine), and exsolvation of polymers by diffusional removal of non-water solvent molecules.

- 5 Degradable linkages in the polymers include esters, orthocarbonates, anhydrides, amides and peptides, acetals, phosphazane linkages, and Schiff base adducts. Examples of groups forming suitable ester linkages include hydroxy acids, such as lactic, glycolic, hydroxybutyric, valerolactic and hydroxycaproic. Examples of
- 10 anhydride-forming groups include oxalic, malonic, succinic, glutaric, adipic, suberic, azelaic sebacic, maleic, fumaric and aspartic. Examples of carbonate-forming compounds include trimethylene carbonate.

- In another aspect, the polymers may be crosslinkable *in situ*. Crosslinking may be by any suitable chemical means. If chemically
- 15 crosslinked, at least one of the polymer and the linkage formed must be biodegradable. Examples of biodegradable linkages include Schiff bases, anhydrides, disulfides, and acetals. Examples of other linkages, not necessarily biodegradable, include epoxy (oxirane) groups, urethanes, ester, ethers, amides, and sulfones. Linkages involving carbon-carbon
- 20 double bonds may be formed by a variety of means, including the polymerization of ethylenically-unsaturated groups. These may include (meth)acryl, vinyl, allyl, styryl, cinnamoyl, and alkenyl groups. Such reactions can be initiated by thermal, chemical, radiative or photochemical means. It is known that most chemically crosslinkable groups and
- 25 molecules will tend to crosslink in the presence of radioactive materials, and are preferably mixed with radioactive materials just before application.

- In another aspect, the biodegradable polymer is dissolved in a solvent other than water (an "organic" solvent, broadly construed to
- 30 include any biocompatible non-aqueous solvent) and deposited at the site, and precipitated as the organic solvent diffuses away from the site, forming a depot. The organic solvent must not cause undue damage to

-5-

the tissue at the site. This will vary, depending on the tissue and on the condition to be treated. In many applications, ethanol, isopropanol, mineral oil, vegetable oil, and liquid silicones may be suitable.

The biodegradable polymer, and any solvent or adjuvant included
5 in the composition, must further be sufficiently biocompatible for the purposes of the therapy. A biocompatible material is one which arouses little or no tissue reaction to its implantation, and where any reaction is of limited extent and duration. The extent of irritation which is tolerable, or which will be elicited, depends on the site of application. For example,
10 many polymers are minimally irritating on the skin, or within the digestive tract, while only a few polymers are acceptable in the peritoneum. Many materials of high biocompatibility (minimally irritating) are non-ionic and, after application, contain few reactive or potentially reactive groups. Preferred examples of such materials are
15 poly(alkylene oxides), such as polyethylene glycols, poloxamers, meroxapols and the like.

The depot formed by local deposition of an appropriate biodegradable polymer, normally in combination with the radioactive material at the time of deposition, will be structured to release the
20 radioactive material in a known and predictable manner during biodegradation of the depot. The combined effects of radioactive decay and of controlled release will determine the total energy deposited into the target tissue. Numerous means are known for controlling the release rate of a material from a depot. These include diffusion of the material
25 through a solid polymer; diffusion of the material through pores in a polymer, or in a gel formed from the polymer; burst release of a material on rupture of a compartment; exposure of material to the environment due to erosion of the polymer; slow dissolution of material from a solid form which is maintained in place by the polymer; release of diffusional
30 restrictions on a material by degradation of a solid polymer, a polymeric coating or a gel; release of a material from a degradable linkage to a polymer, or to a carrier material contained in or on a polymer; and

-6-

- de-binding of a reversible association between a material and a polymer, or a carrier material contained in or on a polymer. Combinations of such means may be used to obtain an optimal release profile. For example, a small radiolabelled molecule may be embedded in a degradable
- 5 microsphere, from which it is slowly released by a combination of diffusion and degradation of the microspheres. The microspheres in turn are restrained at the site of therapy by a polymeric gel formed *in situ*, which itself provides minimal diffusion barriers and further gradually degrades. Selection of the relative degradation rates of the gel and of the
- 10 microspheres will influence the total radiation dose administered to the site of therapy. As used herein, microspheres includes microparticles, microcapsules, liposomes, lipid particles, and other formulations of similar size and function.

Radioactive materials

- 15 Any radioactive material may be used. Standard radionuclides which have been used for local radiotherapy may be used, such as radionuclides of iodine, iridium, radium, cesium, yttrium or other elements.

- Preferred radioisotopes are those which have a particle range in
- 20 tissue which is concordant with the thickness of the layer of tissue to be treated. Information on particle ranges is readily available. For example, it is known that about 90% of the energy from a ^{14}C (carbon-14) source will be absorbed in about the first 70 microns of tissue, and similar distances will be found for sulfur-35 and phosphorous-33, since their
- 25 emitted particles are of the same kind as ^{14}C (beta particles) and of similar energies. More energetic beta particles would have a longer range, such as those of phosphorous-32, which has a maximum range of about a centimeter and thus can be used to treat thicker tumors, or blood vessels
- 30 having multi-millimeter thick medial layers. Very high energy emissions, whether of beta particles or of other forms, are generally less preferred because their emissions may exit from the body, thereby causing shielding problems.

-7-

The radioisotope must be administered in a pharmaceutically acceptable form. The form must be biocompatible, as described above. The form must also be capable of remaining at the site of application for a controlled length of time, in combination with a means for control of local delivery. For example, the radioisotope could be in the form of an element, an inorganic compound, an organic compound, or attached to a larger molecule, such as a polymer. In the last case, incorporation could be into a backbone group; as a side group, preferably covalently bonded; or as a ligand, bound to a suitable binding group on the polymer. A binding group could be a non-biological binding group, such as a chelator for metal ions; or a biological group for binding, such as avidin for biotin. Likewise, the polymer could be biological, such as a protein, a polysaccharide or a nucleic acid; or it could be synthetic, such as a polyalkylene glycol or a poly(meth)acrylate.

Immobilization of Ions in a Gel

Radioactive ions can be directly immobilized in a gel. In one embodiment, they may be locally converted to a low-solubility salt form, for example by precipitation with an appropriate salt, e.g., as calcium phosphate, or as a ligand on a polymer, or as a cofactor bound to a biological molecule.

In a preferred embodiment, radioactive ions are immobilized in a gel by chelation. A chelator can be covalently immobilized in a gel. The covalently linked chelator ('host') in turn can immobilize the metallic ion ('guest').

Polymerizable macromers or small molecules can be synthesized bearing an appropriate chelator connected to the backbone. An example of a suitable molecule would be one which has one end(s) of the central backbone (e.g., a polyalkylene oxide, such as polyethylene glycol (PEG) or polypropylene oxide/polyethylene oxide (PPO/PEO) bearing a chelator, optionally attached through a spacer group such as a hydroxyacid. The other end(s) of the PEG backbone would carry a polymerizable bond, with or without spacer groups. This requires a backbone having two or

-8-

more functionalizable ends.' The presence of the backbone is optional; a chelating group could be directly coupled to a reactive group, such as an acryl, allyl or vinyl group, which would participate in the formation of a gel.

- 5 An example of a chelator ('host') is the polyazamacrocyclic cyclam 1,4,8,11-tetra azacyclo tetradecane which is known to form thermodynamically and kinetically stable complexes with Tc-99m ('guest'), a metal ion used for medical applications.

- 10 An example of a guest is technetium-99m, a γ -emitter for clinical applications, which emits only γ -radiation, has a low radiation energy and a short half-life of only 6 hrs. Tc-99m can be used for monitoring physiological changes using scintigraphy, a highly sensitive γ -radiation-based technique used in most hospitals.

- 15 These chelator-bearing macromonomers can be delivered as solutions and 'gelled' in the target site using polymerizable crosslinkers (e.g., PEG with acrylate endgroups linked to the PEG by biodegradable spacers)). The degradation and other physical property of the resulting hydrogel can be tailored to desired specifications.

The significance of such a gel is that:

- 20 1. Such hydrogels can be formed *in situ* and can bear a γ -emitter or other medically useful isotope for various medical applications.
2. Since databases for various chelators are available from literature, it is straightforward to find an appropriate chelator to selectively immobilize a particular metal ion within a hydrogel.
- 25 3. Other possible applications of the concept include localized delivery or immobilization of medically useful nuclides, localized delivery of physiologically beneficial (and therapeutic) metal ions or other charged species.

Medical Applications

- 30 Applications of this technology include the local treatment of tumors, cancer, and other unwanted growths (e.g., atheromae, papillae); inhibition of scarring or healing to prevent excessive scar formation or

keloid formation; preservation of surgically-created conduits, for example inhibition of healing over of the sclera following a filtration procedure for glaucoma; prevention of fibrosis and of capsule formation; and prevention of restenosis following angioplasty.

5 *Methods of Application*

The local depot can be placed at the site to be treated by any of several methods. For external application, a preformed depot can be applied and secured by appropriate adhesives. An external application would also require appropriate means for prevention of migration of the radioactive material. For internal applications, the depot-forming polymer, preferably in combination with the radioactive material and any required excipients, accessory materials, and drug delivery means, is typically administered in a fluent form to the site of application by a delivery device, and caused or allowed to solidify at the site. Delivery devices can include percutaneous means such as catheters, cannulae, and needles; or means applied through natural or surgically created openings or through temporary openings, such as those created by trocars, using syringes, brushes, pads, or brushes. Similar means are used to apply any stimuli required to form the depot from the fluid polymer material. For example, light may be brought to a remote site via an optical fiber, or a device similar to a laparoscope, to cause polymerization in a depot, or a chemical could be applied by means similar to those used for the depot-forming mixture.

Dose control

25 The method provides three ways of controlling the total dose delivered to a site, while simultaneously controlling exposure to other areas of the body. First, the total amount of isotope can be varied. Second, the half-life of the isotope can be selected; this provides an upper limit of the applied dose. Third, the lifetime of the radioisotope in the local delivery depot can be controlled.

30 For example, if the radioisotope is a macromolecule, then the depot could be a gel, and the rate of release of the macromolecule from

-10-

the gel can be controlled by making the gel sufficiently dense so that the macromolecule is released only as the gel degrades. Such gels are known; for example, the gels described by U.S. Patent No. 5,410,016 to Hubbell et al. are suitable.

- 5 If the radioisotope is a small molecule, rather than a macromolecule, its rate of release can be controlled by embedding it in a solid bioerodable material, such as polylactide, polycaprolactone, a polyanhydride, or a polymerized biomaterial, such as protein. Then the small molecule is released by a combination of diffusion through the material, and erosion of the material, each of which is adjustable.
- 10 Alternatively, the rate of release of a radioisotope may be regulated by selecting the strength of interaction of the molecule with its environment. For example, if both the molecule and the depot are relatively hydrophobic, then the molecule will diffuse out of the depot relatively slowly. If it is not practical to make the depot hydrophobic, then the molecule can be included in more hydrophobic microparticles, such as polymeric microparticles, liposomes, emulsions, etc., which in turn are embedded within a hydrophilic depot.
- 15

- 20 The present invention will be further understood by reference to the following non-limiting examples.

Example 1: Immobilization of a radionuclide in an interfacially deposited gel.

- A radionuclide (^{125}I or ^{131}I or other radionuclide) is deposited in an interfacial hydrogel following angioplasty, either coronary or peripheral, or intravascular stent placement, or carotid artery stent, or an arterectomy.
- 25 The incorporated radionuclide is chosen to provide a total of exposure of at least 1500 cGy to the arterial wall. The delivered dose is adjusted by choosing the amount of incorporated radionuclide and is further controlled by choosing a formulation of hydrogel with a different persistence at the site of deposition.
- 30 The duration of exposure at the site of deposition can be controlled by adjusting the biodegradable moieties of

the hydrogel or by changing the density of crosslink of the polymer at the site.

Example 2: Local radiotherapy from a polymer applied via catheterization.

- 5 Local radiotherapy can be applied to any tumor which is accessible by a vascular catheter. This technique is particularly applicable to either highly vascularized tumors or tumors which have a single dominant arterial vascular supply. This would provide a method for treatment particularly applicable to renal cell carcinoma, hepatoma, sarcomas,
- 10 cancers of the head and neck, and central nervous system tumors. In this example, radioactive microspheres containing yttrium-90 are incorporated in a hydrogel that is deposited in the artery supplying a tumor. The local tumor volume in the area of deposition is radiated while the microspheres are immobilized at the site of deposition. On degradation of the
- 15 hydrogel, the microspheres are released and redeposited in the distal microcirculation, where they provide continued radiation treatment. The exposure at the site of an initial deposition can be regulated by controlling the rate of hydrogel degradation, either by adjusting the biodegradable moieties in the hydrogel or the density of crosslinking. The microspheres
- 20 can be chosen for a longer time of degradation or elimination of greater than 320 hours, when five half-lives of the implanted yttrium-90 have expired and the vast majority of radioactive decay has occurred.

We Claim:

1. A method for local radiotherapy at a site in a patient, comprising forming a polymeric depot at a site at which therapy is to be administered, wherein the depot comprises one or more radioisotopes in combination with a depot-forming biodegradable biocompatible polymeric material.
2. The method of claim 1, in which the depot is a hydrogel.
3. The method of claim 1, in which the depot is a solid polymer applied in a first fluent state and converted to a second less fluent state upon application to tissue.
4. The method of claim 1 wherein the polymer is chemically coupled to the radioisotopes.
5. The method of claim 1 wherein the polymer is conjugated to the radioisotopes via a chelating agent coupled to the polymer.
6. The method of claim 1 wherein the depot comprises microspheres comprising radioisotopes.
7. The method of claim 6 wherein the microspheres are biodegradable at a different rate than the depot.
8. A composition for local radiotherapy, comprising one or more radioisotopes in combination with a depot-forming material, wherein the depot-forming material is a biodegradable, biocompatible polymer and can be formed into a depot *in vivo* at a selected site.
9. The composition of claim 8, in which the depot is a hydrogel.
10. The composition of claim 8, in which the depot is a solid polymer applied in a first fluent state and converted to a second less fluent state upon application to tissue.
11. The composition of claim 8 wherein the polymer is chemically coupled to the radioisotopes.
12. The composition of claim 8 wherein the polymer is conjugated to the radioisotopes via a chelating agent coupled to the polymer.

-13-

13. The composition of claim 8 wherein the depot comprises microspheres comprising radioisotopes.

14. The composition of claim 13 wherein the microspheres are biodegradable at a different rate than the depot.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 97/02075

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K51/12 A61K51/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 87 06241 A (CARBOMATRIX AB) 22 October 1987 see page 1, line 31 - page 28 see page 4, line 11 - line 14 see page 5, line 32 - page 6, line 5; claims 1,11; example 3 ---	1,2,6, 8-12
X	US 4 115 540 A (DIGENIS GEORGE A ET AL) 19 September 1978 see column 2, line 4 - line 12; claims 1,6,7,10 ---	1,4-6,8, 11-14
X	WO 96 03112 A (SYNGENIX LTD ;FILLER AARON GERSHON (GB); LEVER ANDREW M L (GB)) 8 February 1996 see page 5, line 21 - page 6, line 7 --- -/-	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is used to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "Z" document member of the same patent family

Date of the actual completion of the international search

6 May 1997

Date of mailing of the international search report

14.05.97

 Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/02075

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 125, no. 9, 26 August 1996 Columbus, Ohio, US; abstract no. 109075, NING, SHOUCHEG ET AL.: "Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel" XP002030550 see abstract & RADIOTHER. ONCOL. (1996), 39(2), 179-189 CODEN: RAONDT;ISSN: 0167-8140, 1996, ---	1-4,8
A	DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US AN=96033224, XP002030552 see abstract & JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 47, no. 7, July 1995, ENGLAND, pages 581-584, DURRANI A.M. ET AL.: "PRECORNEAL CLEARANCE OF MUCOADHESIVE MICROSPHERES FROM THE RABBIT EYE." ---	1
X	DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US AN=90335606, XP002030553 see abstract & BRITISH JOURNAL OF RADIOLOGY, vol. 63, no. 749, May 1990, ENGLAND, pages 346-348, BALL A.B. ET AL.: "SILICONE IMPLANT TO PREVENT VISCERAL DAMAGE DURING ADJUVANT RADIOTHERAPY FOR INTRAPERITONEAL SARCOMA." ---	1,2
X	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 76, no. 12, December 1987, WASHINGTON US, pages 935-939, XP002030549 TIMO LAAKSO ET AL.: "BIODEGRADABLE MICROSPHERES X: SOME PROPERTIES OF POLYACRYL STARCH MICROPARTICLES PREPARED FROM ACRYLIC ACID-ESTERIFIED STARCH." see page 935, column 1, paragraph 1 ---	1,2,4,6

-/-

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/02075

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 109, no. 15, 10 October 1988 Columbus, Ohio, US; abstract no. 125450, FURUKAWA, SHIGEO ET AL: "Catheter for in situ cavity irradiation for radiotherapy" XP002030551 see abstract & JP 62 254 773 A (NIPPON OIL CO., LTD., JAPAN) ---	1
X	WO 96 00588 A (NYCOMED IMAGING AS ;COCKBAIN JULIAN R M (GB); LADD DAVID LEE (US)) 11 January 1996 see page 11 see page 13, line 13 - line 27; claims 1,3-16,22 -----	1,4-6, 8-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/US 97/02075

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8706241 A	22-10-87	AU 7285087 A	09-11-87
US 4115540 A	19-09-78	NONE	
WO 9603112 A	08-02-96	NONE	
WO 9600588 A	11-01-96	AU 2799695 A	25-01-96
		CA 2191878 A	11-01-96
		EP 0767679 A	16-04-97